Envestnet Asset Management
MRTX

Envestnet Asset Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Envestnet Asset Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-4,911
Closed -$289K – 4329
2023
Q4 		$289K Sell
4,911
-77,502
-94% -$4.36M ﹤0.01% 3644
2023
Q3 		$3.59M Buy
82,413
+59,968
+267% +$2.14M ﹤0.01% 2019
2023
Q2 		$811K Buy
22,445
+2,502
+13% +$103K ﹤0.01% 2899
2023
Q1 		$741K Buy
19,943
+3,325
+20% +$150K ﹤0.01% 2877
2022
Q4 		$753K Buy
16,618
+1,419
+9% +$91.8K ﹤0.01% 2845
2022
Q3 		$1.06M Buy
15,199
+1,075
+8% +$79.5K ﹤0.01% 2524
2022
Q2 		$948K Buy
14,124
+6,056
+75% +$385K ﹤0.01% 2638
2022
Q1 		$663K Buy
+8,068
New +$825K ﹤0.01% 2954
2021
Q4 		– Sell
-1,213
Closed -$215K – 3966
2021
Q3 		$215K Buy
+1,213
New +$195K ﹤0.01% 3472
2021
Q2 		– Sell
-1,593
Closed -$273K – 3715
2021
Q1 		$273K Buy
1,593
+219
+16% +$43.4K ﹤0.01% 3188
2020
Q4 		$302K Sell
1,374
-552
-29% -$119K ﹤0.01% 2924
2020
Q3 		$320K Buy
+1,926
New +$264K ﹤0.01% 2702

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Envestnet Asset Management's MRTX Position: Q1 2024 in Review

Envestnet Asset Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 4,911 shares — an estimated $289K sold.

Envestnet Asset Management first reported a position in MRTX in Q3 2020 and held it in 12 quarters. The position peaked at $3.59M in Q3 2023. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • Envestnet Asset Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Envestnet Asset Management sold 4,911 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $289K.
  • Envestnet Asset Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2020 and held it in 12 quarters.
  • Envestnet Asset Management's Mirati Therapeutics, Inc. Common Stock position peaked at $3.59M in Q3 2023.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Envestnet Asset Management's 13F filing for Q1 2024, filed 13 May 2024.